Huma secures £61.7m Series D investment from backers including AstraZeneca to launch its cloud platform.
The Series D round was backed by strategic investors including AstraZeneca, HAT SGR, Hitachi Ventures, and Leaps by Bayer.
Global healthcare AI company that provides regulated digital health platforms for care and research. Its technology supports thousands of hospitals and clinics worldwide.
Global healthcare AI company Huma has secured £61.7m in a Series D funding round to support the rollout of its newly launched Huma Cloud Platform. The investment saw participation from a range of strategic and financial backers, including AstraZeneca, Hat Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures, and Leaps by Bayer. HSBC Bank plc advised the company on the transaction.
The newly raised capital coincides with the deployment of the Huma Cloud Platform, a technology ecosystem designed to provide no-code configuration of regulated disease management tools. The company intends to leverage this infrastructure to reduce the time required to build and deploy digital health projects from years to days.
From the founder
"I am thankful for the support of our new and existing shareholders, helping our vision become a reality, which we are closer to than ever before. We are here to accelerate the adoption of digital and AI across care and research, and we do that by making the building of digital health solutions for care and research easy. We like to think of Huma Cloud Platform much like Shopify but for digital health instead of e-commerce. We believe when digital and AI are scaled, they become affordable for both the poor and the rich. This will help us transition medicine from being reactive to proactive."
Dan Vahdat
Founder and CEO at Huma
Investor perspective
"We have known Huma for several years and we’ve been impressed by their remarkable progress. We have seen this first-hand. They have demonstrated strong growth and excellent metrics. With their next-generation AI capabilities and Huma Cloud platform, Huma can partner with pharma companies to deliver efficient digital health solutions to patients focused on predictive and proactive care."
Juergen Eckhardt
EVP, Head of Leaps by Bayer and Pharmaceuticals Business, Development & Licensing, Leaps by Bayer
Use of funds
- 01Continue product development